Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 9/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.54 |
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.54 |
| ▸ | CMA1 | P23946 | 2/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | DPP3 | Q9NY33 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alacepril SCHEMBL11460465 | 1.00 | ACE (0.55) | ACESLC6A2ACE2CMA1OPRM1 | |
| Alacepril SCHEMBL5058556 | 1.00 | ACE (0.55) | ACESLC6A2ACE2CMA1OPRM1 | |
| Alacepril SCHEMBL20126832 | 1.00 | ACE (0.55) | ACESLC6A2ACE2CMA1OPRM1 | |
| Alacepril SCHEMBL683027 | 1.00 | ACE (0.55) | ACESLC6A2ACE2CMA1OPRM1 | |
| Alacepril SCHEMBL3204613 | 1.00 | ACE (0.55) | ACESLC6A2ACE2CMA1OPRM1 | |
| Alacepril SCHEMBL28035498 | 1.00 | ACE (0.55) | ACESLC6A2ACE2CMA1OPRM1 | |
| Alacepril SCHEMBL677447 | 1.00 | ACE (0.55) | ACESLC6A2ACE2CMA1OPRM1 | |
| Alacepril SCHEMBL11458085 | 0.95 | ACE (0.51) | ACESLC6A2ACE2CMA1OPRM1 | |
| SCHEMBL11282561 | 0.93 | SLC6A2 (0.56) | ACESLC6A2CMA1OPRM1 | |
| SCHEMBL683119 | 0.93 | SLC6A2 (0.56) | ACESLC6A2CMA1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 8887 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026087680-A1 | TREATMENT FOR CARDIOVASCULAR DISEASE | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| EP-4595974-A2 | THERAPEUTIC COMBINATIONS OF TDFRPS AND ADDITIONAL AGENTS AND METHODS OF USE | Carlson, William D. (US) | 2025-08-06 | — | — | EP | claimed |
| US-20250082608-A1 | TREATMENT AND PREVENTION OF GLOMERULAR DISEASE | SINGAPORE HEALTH SERVICES PTE LTD. (SG) | 2025-03-13 | — | — | US | claimed |
| US-20240374587-A1 | MEDICINE FOR PREVENTION AND TREATMENT OF DISEASES LINKED TO ANTI-OBESITY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2024-11-14 | — | — | US | claimed |
| EP-4448096-A1 | TREATMENT AND PREVENTION OF GLOMERULAR DISEASE | Singapore Health Services Pte. Ltd. (SG) | 2024-10-23 | — | — | EP | claimed |
| WO-2024210922-A1 | COMPOSITIONS FOR ANTIHYPERTENSIVE DRUGS | INNOVATOR THERAPEUTICS, LLC. (US) | 2024-10-10 | — | — | WO | claimed |
| EP-3083573-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME LLC (US) | 2024-08-07 | — | — | EP | claimed |
| EP-4400105-A1 | MEDICINE FOR PREVENTION AND TREATMENT OF DISEASES LINKED TO ANTI-OBESITY ACTIVITY | Shionogi & Co., Ltd (JP) | 2024-07-17 | — | — | EP | claimed |
| US-20240123033-A1 | THERAPEUTIC COMBINATIONS OF TDFRPs AND ADDITIONAL AGENTS AND METHODS OF USE FOR THE REVERSAL OF FIBROSIS | Therapeutics By Design, LLC (US) | 2024-04-18 | — | — | US | claimed |
| US-11931341-B2 | Compositions and methods for the treatment and prevention of muscular dystrophy | UNIVERSITY OF LOWA RESEARCH FOUNDATION (US) | 2024-03-19 | — | — | US | claimed |
| EP-0391462-A1 | Synergistic compositions containing ketanserin | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-10-10 | — | — | EP | claimed |
| EP-0272177-B1 | PHARMACEUTICAL COMPOSITION CONTAINING DILTIAZEM AND AN INHIBITOR OF THE ENZYME-TRANSFORMING ANGIOTENSIN | SYNTHELABO (FR) | 1990-07-04 | — | — | EP | claimed |
| EP-0363671-A2 | Use of ACE inhibitors against the formation of neo-intima after vascular infliction | F. HOFFMANN-LA ROCHE AG (CH) | 1990-04-18 | — | — | EP | claimed |
| EP-0351017-A2 | Pharmaceutical composition useful for the treatment of cardiovascular diseases | ZAMBON GROUP S.p.A. (IT) | 1990-01-17 | — | — | EP | claimed |
| EP-0320097-A1 | Controlled absorption diltiazem formulations | ELAN CORPORATION, Plc (IE) | 1989-06-14 | — | — | EP | claimed |
| EP-0220107-A2 | Use of angiotensin-converting enzyme inhibitors in macular degeneration | MERCK & CO. INC. (US) | 1987-04-29 | — | — | EP | claimed |
| US-4656188-A | Ace inhibitors in macular degeneration | MERCK & CO., INC. (US) | 1987-04-07 | — | — | US | claimed |
| EP-0007477-B1 | 1-(3-MERCAPTO-2-METHYLPROPANOYL)PROLYL AMINO ACID DERIVATIVES AND SALTS THEREOF, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS | Dainippon Pharmaceutical Co., Ltd. (JP) | 1982-04-28 | — | — | EP | claimed |
| US-4248883-A | ANTIHYPERTENSION AGENTS | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1981-02-03 | — | — | US | claimed |
| EP-0007477-A1 | 1-(3-Mercapto-2-methylpropanoyl)prolyl amino acid derivatives and salts thereof, processes for their preparation, and pharmaceutical compositions containing such compounds | Dainippon Pharmaceutical Co., Ltd. (JP) | 1980-02-06 | — | — | EP | claimed |